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In Clinical Science
Commentary "Does epilepsy run in families?" As health care providers in the epilepsy field, many of us are asked this question frequently by patients and family members. A quick search of epilepsy advocacy websites on the Internet reveals how often this question is posted on discussion boards and how variable are the answers presented, even when the literature is accurately quoted. A rigorous data-driven answer is important for many reasons: From a clinical standpoint, understanding familial epilepsy risk enables providers to deliver the appropriate counseling, reassurance, and surveillance for patients and families. This investigation has critical translational implications as well. The field of genetic exploration of the epilepsies is advancing rapidly, most recently with the successful recruitment of the Epilepsy Phenome Genome Project (1), the advent of big data sharing and more accessible genome-wide sequencing. However, these same advances demonstrate ever-increasing layers of complexity (2) . As a complementary line of investigation, the role of clinical epidemiology to inform genetic studies grows ever more essential.
Lennox performed the earliest large family study in epilepsy in the early 1950s (3), demonstrating that the risk of epilepsy was increased for close relatives of patients with epilepsy. The increase was present for both "essential" and "symptomatic" epilepsy but was higher in the essential group. Many studies have been published in this area since, using a wide range of study designs and populations. In the most recent approach to this question, Peljto et al. embarked on a large-scale examination of familial risk in epilepsy. The group designed a study meant to address some of the limitations of prior reports, utilizing a team that included investigators who have been involved in many of the seminal previous studies in this area. Almost all previous studies of familial risk of epilepsy have had potentially serious methodological limitations. Our goal was to address these limitations and provide more rigorous estimates of familial risk in a population-based study. We used the unique resources of the Rochester Epidemiology Project to identify all 660 Rochester, Minnesota residents born in 1920 or later with incidence of epilepsy from 1935-94 (probands) and their 2439 first-degree relatives who resided in Olmsted County. We assessed incidence of epilepsy in relatives by comprehensive review of the relatives' medical records, and estimated age-specific cumulative incidence and standardized incidence ratios for epilepsy in relatives compared with the general population, according to proband and relative characteristics. Among relatives of all probands, cumulative incidence of epilepsy to age 40 was 4.7%, and risk was increased 3.3-fold (95% confidence interval 2.75-5.99) compared with population incidence. Risk was increased to the greatest extent in relatives of probands with idiopathic generalized epilepsies (standardized incidence ratio 6.0) and epilepsies associated with intellectual or motor disability presumed present from birth, which we denoted 'prenatal/developmental cause' (standardized incidence ratio 4.3). Among relatives of probands with epilepsy without identified cause (including epilepsies classified as 'idiopathic' or 'unknown cause'), risk was significantly increased for epilepsy of prenatal/developmental cause (standardized incidence ratio 4.1). Similarly, among relatives of probands with prenatal/developmental cause, risk was significantly increased for epilepsies without identified cause (standardized incidence ratio 3.8). In relatives of probands with generalized epilepsy, standardized incidence ratios were 8.3 (95% confidence interval 2.93-15.31) for generalized epilepsy and 2.5 (95% confidence interval 0.92-4.00) for focal epilepsy. In relatives of probands with focal epilepsy, standardized incidence ratios were 1.0 (95% confidence interval 0.00-2.19) for generalized epilepsy and 2.6 (95% confidence interval 1.19-4.26) for focal epilepsy. Epilepsy incidence was greater in offspring of female probands than in offspring of male probands, and this maternal effect was restricted to offspring of probands with focal epilepsy. The results suggest that risks for epilepsies of unknown and prenatal/developmental cause may be influenced by shared genetic mechanisms. They also suggest that some of the genetic influences on generalized and focal epilepsies are distinct. However, the similar increase in risk for focal epilepsy among relatives of probands with either generalized (2.5-fold) or focal epilepsy (2.6-fold) may reflect some coexisting shared genetic influences.
Does Epilepsy Run in Families? Getting Closer to the Answer
An important aspect of the current study is that it is population-based rather than being conducted through a tertiary care setting. While tertiary care centers offer an enriched population that is valuable for many studies in epilepsy, the generalizability of findings from this population for epidemiologic purposes can be a concern. This is especially true for assessing familial risk of disease. For example, patients from families where epilepsy occurs in more than one individual may be more likely to be treated in a tertiary care center than are isolated cases. Furthermore, the population receiving care at tertiary care epilepsy centers is likely to overrepresent persons with more severe disease and thus may affect the classification findings. While population-based familial studies are logistically challenging, there are a number of regions in the United States where a large percentage of the population obtains their care through either a large single or collaborative medical system, and these settings naturally lead to opportunities such as the one utilized by this group.
The Rochester Epidemiology Project is one such system and has been the setting for two previous population studies in epilepsy (4, 5) . The current investigation is built from the Genetic Epidemiology of Seizure Disorders in the Rochester study, developed by Ottman et al. (6) from the resources of the Rochester project. The reported advantages in the current Rochester study over the two preceding ones include an examination of epilepsy in all descendants and parents (rather than just offspring), and the inclusion of probands with incident epilepsy occurring at any age (rather than childhood onset). The current study further included probands whose epilepsy was symptomatic, unlike previous studies that included only epilepsy of unknown cause. As in the prior studies, the extensive medical record resources accessible through the Rochester project (largely derived from Mayo Clinic) provided extensive information about probands and family members.
The investigators worked with a previously described cohort that comprised all 910 residents of Rochester, MN, with incident single unprovoked seizure or epilepsy between 1935-1994 and who were born after 1920. In the current study, only the subset with incident epilepsy was included, consisting of 660 probands. Using broadly based diagnostic codes, the medical records of all first-degree relatives of these probands who resided in Olmstead County and participated in the Rochester Epidemiology Project were screened to identify any potential relatives with epilepsy. A control group of relatives without epilepsy codes were screened and confirmed the reliability of this design. Standardized incidence ratios (SIRs) were calculated as the ratio of observed-to-expected number of relatives with epilepsy, with the expected incidence based on age, sex, and date matched population incidence rates. Age-specific cumulative incidence of epilepsy up to age 40 was calculated for the first degree relatives as well.
The risk of epilepsy among family members of probands was high. Overall, relatives of probands had a cumulative incidence of epilepsy to age 40 of 4.7%, with a more than threefold risk compared with population incidence (SIR 3.3). This risk was not equally distributed across epilepsy classifications. The highest incidence of epilepsy was in relatives of probands with idiopathic generalized epilepsies, who had a sixfold increased risk over the general population. Risk was overall higher for relatives of probands with generalized (SIR 5.0) rather than focal (SIR 2.1) epilepsies. In all categories, a prenatal/developmental etiology in the proband was associated with significantly higher epilepsy risk in first degree relatives, with SIRs ranging from 3.6-4.8.
Perhaps even more striking was the association between types of epilepsy in the proband and relative. For example, the risk of generalized epilepsy in a relative of a proband with generalized epilepsy was eightfold that of the general population (SIR 8.), and when restricted specifically to IGE, the risk was as high as elevenfold! For focal epilepsy overall, there was an increased risk for relatives to have focal (SIR 2.6) but not generalized (SIR 1.0) epilepsy. However, focal epilepsy without a known cause in a proband was associated with a fourfold increased risk for focal epilepsy without a known cause in a family member (SIR 4.0).
Finally, there were significant differences between proband gender and epilepsy incidence in offspring. Children of mothers with epilepsy had a fivefold increase in epilepsy risk and a cumulative incidence to age 40 of 5.4%. This increase incidence was not present for children of proband fathers for the overall group. For offspring of probands with generalized epilepsy, however, children of both genders had a sevenfold (male probands) to nearly ninefold (female probands) increase in epilepsy risk.
Many previous studies in this area have demonstrated similar findings, including the higher epilepsy risk in generalized over partial epilepsy (e.g., 7) and the maternal effect (e.g., 8 ). The current study has an optimal population-based study design, and it is particularly robust and inclusive, suggesting that these findings are likely to be strongly generalizable. The data on the high familial clustering in IGE is particularly interesting, given the newly revised ILAE classification (9) that terms epilepsies previously classified as IGE as "genetic generalized epilepsies. " It would have been interesting if the authors had included subgroups in each classification category; for example, familial risk in frontal versus temporal lobe epilepsy or absence versus juvenile myoclonic epilepsy. As with other studies, a large group of unclassified patients may have some bearing on the results, and this is a limitation that might be mitigated in a study of individuals diagnosed more recently than 1994. Other factors associated with familial risk in other studies would also be of interest; for example, younger proband age, nature of the relation (sibling vs other first-degree relative), and presence of febrile convulsions as reported in a large Indian family study of epilepsy (10) .
Does this paper extend our knowledge of familial clustering in epilepsy? It appears to go a long way. The risk values presented are credible and consistent with prior reports. The risk stratification is expanded based on more specific classification and etiological factors. The numbers emerging from this study should be of help to clinicians and researchers alike. The authors should be encouraged to continue mining this valuable data set for even more specific and current familial risk assessments.
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